Table 4.

Rechallenge with an ICPi after ICPi-AKI

VariableAll Rechallenged (n=31)Recurrent AKI (n=7)No AKI (n=24)P Value
Months from AKI to rechallenge1.80 (1.23–10.97)1.4 (0.73–1.63)2.05 (1.48–13.95)0.03
Complete response, n (%)16 (52)2 (29)14 (58)0.22
SCr at rechallenge, mg/dl1.30 (1.11–2.00)1.30 (1.22–1.60)1.39 (1.11–2.01)0.98
On GC at rechallenge, n (%)12 (39)3 (43)9 (38)0.99
Prednisone dose, mg/d10 (5–15)10 (5–10)10 (5–20)0.91
Rechallenged with same ICPi, n (%)27 (87)7 (100)20 (83)0.55
Months from rechallenge to AKINA1.53 (0.60–4.93)NANA
SCr at recurrent AKI, mg/dlNA2.70 (1.71–4.80)NANA
Age at ICPi initiation, yr61 (57–71)59 (58–61)68 (56–71)0.29
Female, n (%)8 (26)1 (14)7 (29)0.64
Autoimmune disease, n (%)2 (6)0 (0)2 (8)0.99
Extrarenal irAE, n (%)17 (55)5 (71)12 (50)0.41
Stage 3 AKI, n (%)13 (42)2 (29)11 (46)0.67
Biopsied, n (%)12 (39)3 (43)9 (38)0.99
  • Data are shown as median (IQR) and n (%). GC, glucocorticoids; SCr, serum creatinine; irAE, immune-related adverse event.